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between 0.84 and 0.90 without significant differences. 
Interestingly, the discriminative power of the single IPSS ites 
was different and dramatically changed over time: only IPSS6 
(straining) always showed a poor value at each time (AUC: 
0.55-0.65). All the remaining IPSS items showed not 
significantly (p>0.07) different AUCs at baseline (0.71-0.76), 
while exhibiting very different patterns after RT. IPSS2 
(frequency), IPSS4 (urgency) and IPSS7 (nocturia) showed the 
highest performances in the acute phase (AUC:0.77-0.87 at 
RT end and at 3 months). At 24 months, weak stream showed 
the highest AUC (0.87) while the remaining items ranged 
between 0.69 and 0.76. Very importantly, the AUC of ICIQ 
continuously increases from baseline/RT end (AUC=0.62-0.63) 
up to 24 months (AUC:0.82). In Figure 1a/1b the ROC curves 
at the different time intervals for overall IPSS and ICIQ are 
shown; a summary of AUC changes is shown in Figure 1c for 
all scores at baseline, end RT, 12 and 24 months. 
 
 
 
Conclusion: The analysis of a large population of 
prospectively followed patients with PRUS evaluation showed 
that the discriminative power of different symptoms in 
assessing a severely impaired urinary QoL significantly 
changes over time. As expected, the overall IPSS always 
captures a very large fraction of these patients, while the 
predictive value of ICIQ is negligible at baseline and acutely, 
becoming highly discriminative in the long term. 
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Purpose or Objective: In patients with painful bone 
metastases, radiotherapy is an effective treatment. Besides 
symptom control, quality of life (QoL) is an important 
endpoint. We focus on the course of QoL after radiotherapy. 
 
Material and Methods: In the Dutch Bone Metastasis Study, 
1,157 patients with painful bone metastases were 
randomized between one fraction of 8 Gray and six fractions 
of 4 Gray. The study proved equal effectiveness, with a pain 
response of 74%. Patients filled out weekly questionnaires for 
13 weeks and then monthly for two years or until death. 
Three QoL domain scores (physical, psychosocial and 
functional) and a visual analogue scoring of general health 
were studied. Mixed modeling was used to model the course 
of QoL and to study the influence of several characteristics. 
An effect size of ≥ 0.10/0.20 (binary or continuous variable, 
respectively) is considered a small effect and therefore 
clinically relevant. 
 
Results: In general, QoL stabilizes after a month. 
Psychosocial QoL improves temporarily after treatment. The 
level of QoL remains stable for a long time, steeply 
deteriorating at the end of life. For most QoL domains, a high 
pain score and intake of opioids are associated with worse 
QoL, with a small effect size (-0.11 to -0.27). A poor 
performance score is associated with worse functional QoL, 
with a medium effect size of 0.41. 
Figure: The modeled course of QoL after radiotherapy for 
painful bone metastases, represented in survival groups 
(patients surviving less than 3, 3-<6, 6-<12, 12-<18 and 18-
<24 months after randomization). The x-axis represents the 
months after treatment, where month 0 is the baseline 
measurement before treatment and month 1 the first months 
after treatment. The y-axis reflects the domain score of QoL, 
where the average is 0, with a standard deviation of 1. The 
higher the score, the better the QoL. 
Table: Influence of baseline and follow-up variables on QoL 
domains, with effect sizes 
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Conclusion: Although radiotherapy for painful bone 
metastases leads to a meaningful pain response, QoL does 
not improve after treatment. Initially, it remains stable 
followed by deterioration towards the end of life. 
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Purpose or Objective: The incidence of p16-overexpression 
and the role of human papillomavirus (HPV) in cutaneous 
head and neck squamous cell carcinoma (cHNSCC) is unclear. 
In the unknown primary setting, where cHNSCC is a potential 
putative site, p16 status is being used to guide management 
despite varying reports of its incidence in non-oropharyngeal 
sites.  
 
Material and Methods: 143 patients with cHNSCC lymph node 
metastases involving the parotid gland were evaluated for 
p16 expression by immunohistochemistry. Detection of 18 
high-risk HPV subtypes was performed using HPV RNA in situ 
hybridization on a subset of 59 patients. Results were 
correlated with clinicopathological features and outcomes 
 
Results: Median follow up time was 5.3 years. No differences 
were observed in clinicopathological factors based on p16 
status. p16 was positive, intermediate and negative in 45 
(31%), 21 (15%) and 77 (54%) of cases, respectively. No high-
risk HPV subtypes were identified, irrespective of p16 status. 
p16 status was not prognostic for overall (HR 1.08 95% CI 
[0.85 - 1.36], p=0.528), cancer-specific (HR 1.12 95% CI [0.77 
- 1.64], p=0.542) or progression-free survival (HR 1.03 95% CI 
[0.83 - 1.29], p=0.783). Distant metastasis free survival, 
freedom from locoregional failure and freedom from local 
failure were also not significantly associated with p16 status. 
 
Conclusion: p16 positivity is common but not prognostic in 
cHNSCC lymph node metastases. High-risk HPV subtypes are 
not associated with p16-positivity, and do not appear to play 
a role in this disease. HPV testing, in addition to p16-status in 
the unknown primary setting may provide additional 
information in determining a putative primary site. 
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Purpose or Objective: To investigate the prognostic 
significance of tumore-related leukocytosis (TRL) in cervical 
cancer patients treated with definitive radiotherapy 
 
Material and Methods: Between 1986 and 2012, 2,456 
patients with uterine cervical cancer (FIGO stage IA-IB 494, 
stage IIA-IIB 1530, stage IIIA-IIIB 394 and stage IVA 38) who 
received definitive radiotherapy (62.6%) or platinum-based 
chemoradiotherapy (37.4%) consisting of EBRT and ICBT were 
retrospectively analyzed. TRL was defined as WBC count of 
≥9,000/μL on ≥2 occasions at the time of diagnosis and during 
the course of treatment. The neutrophil/lymphocyte ratio 
(NLR) was defined as the absolute neutrophil count divided 
by the absolute lymphocyte count. Locoregional failure free 
survival (LRFFS) and overall survival (OS) were compared 
between patients with or without TRL. 
 
Results: Median age of all patients was 55 years (range, 21-
87) and the median follow-up time was 65.1 months (range, 
0.7-347.8). Among 2,456 patients included in this study, TRL 
was observed in 398 (16%) at the initial diagnosis. Patients in 
TRL(+) group were younger in age and had larger tumor, 
advanced FIGO stage and more common LN metastases (all p 
< 0.05). TRL (+) group showed relatively lower rate of 
complete remission (CR) (90% vs. 97%, p = 0.042).The 10-year 
LRFFS and OS for all patients were 84% and 78%, respectively. 
Compared to TRL(-) group, LRFFS and OS were significantly 
lower in TRL(+) group (10-yr LRFFS: 69% vs. 87%, p <0.001; 
10-yr OS: 63% vs. 81% p < 0.001). After propensity score 
matching by age, FIGO stage, tumor size, LN metastasis, 
histologic subtype and pretreatment hemoglobin (Pre Tx Hb), 
both groups were well matched. The LR control and OS rate 
of TRL (+) group was still significantly lower than those of 
TRL (-) group. In multivariate analysis, advanced FIGO stage, 
non-SqCCa, larger tumor size and TRL were identified as risk 
factors for LRFFS and OS (all p < 0.05). In addition, Pre Tx 
Hb, LN metastasis and high NLR (≥2.5) were also associated 
with poorer OS (all p < 0.05). Among patients with LRF 
(n=345), patients with TRL at the time of recurrence 
accounted for 26% and showed relatively poorer median OS (6 
vs. 12 months, p = 0.001). 
 
Conclusion: This study supports the aggressive nature and 
poor radiation response of cervical cancer with leukocytosis. 
Given the unfavorable features and higher probability of 
treatment failure, optimal therapeutic approach and careful 
monitoring for early detection of recurrence should be 
considered for these patients. 
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Purpose or Objective: Stage II testicular seminoma is highly 
curable with radiotherapy (RT) or multiagent chemotherapy 
(MACT). These modalities have not been prospectively 
compared. Due to the rarity of stage II seminoma, prior 
studies are limited by small sample size.  NCCN guidelines 
recommend RT as the preferred treatment for stage IIA, 
while EUA guidelines equally allow for RT or MACT.  Both 
guidelines are equivocal for stage IIB, and recommend MACT 
for stage IIC. 
 
